Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

• Main Authors: Rancourt Claudine, Bachvarov Dimcho, Barrès Véronique, Lussier Christian, Madore Jason, Normandin Karine, Ling Tak, Ouellet Véronique, Tonin Patricia N, Provencher Diane M, Mes-Masson Anne-Marie
• Format: Article
• Language: English
• Published: BMC 2008-11-01
• Series: BMC Cancer
• Online Access: http://www.biomedcentral.com/1471-2407/8/346

<p>Abstract</p> <p>Background</p> <p>Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined.</p> <p>Methods</p> <p>In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).</p> <p>Results</p> <p>Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.</p> <p>Conclusion</p> <p>This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.</p>